Cellyan Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Net Income	-0.7	-0.03	1.33	1
Depreciation & Amortization	1.09	1.07	0.93	0.71
Loss (Gain) From Sale of Assets	-	-	-0	-
Loss (Gain) From Sale of Investments	0.01	0.04	-	-
Change in Accounts Receivable	-0.21	-0.92	-2.05	-0.93
Change in Inventory	-0.04	0.38	-0.74	-0.19
Change in Accounts Payable	-0.57	0.4	-0.11	0.96
Change in Unearned Revenue	0.45	-0.07	-0.08	0.21
Change in Income Taxes	-0.22	-0.11	0.2	0.02
Change in Other Net Operating Assets	-0.25	-0.19	0.13	-0.05
Operating Cash Flow	-0.43	0.57	-0.39	1.73
Capital Expenditures	-0.06	-0.07	-0.05	-0.11
Sale of Property, Plant & Equipment	-	-	0.03	-
Sale (Purchase) of Intangibles	-0.03	-0.09	-0.04	-0
Investment in Securities	-2.3	-2.3	-	-
Other Investing Activities	-	-	0.01	-0.01
Investing Cash Flow	-2.39	-2.45	-0.04	-0.13
Long-Term Debt Issued	-	1.59	2.14	0.19
Long-Term Debt Repaid	-	-2.52	-1.77	-1.34
Net Debt Issued (Repaid)	-0.48	-0.93	0.37	-1.16
Issuance of Common Stock	4.05	4.3	0.51	-
Other Financing Activities	-0.93	-1.38	-0.35	-
Financing Cash Flow	2.64	2	0.54	-1.16
Foreign Exchange Rate Adjustments	0.01	0.01	0	0
Net Cash Flow	-0.17	0.12	0.1	0.44
Free Cash Flow	-0.49	0.5	-0.45	1.61
Free Cash Flow Margin	-3.01%	2.46%	-2.68%	12.84%
Free Cash Flow Per Share	-0.05	0.05	-0.06	0.24
Cash Interest Paid	0.1	0.1	0.08	0.06
Cash Income Tax Paid	0.29	0.29	-	-
Levered Free Cash Flow	2.44	2.16	-2.93	-
Unlevered Free Cash Flow	2.51	2.22	-2.88	-
Change in Working Capital	-0.83	-0.52	-2.65	0.01

Source: S&P Capital IQ. Standard template. Financial Sources.